SLP-DIAZIP

This brand name is authorized in Nigeria.

Active ingredients

The drug SLP-DIAZIP contains one active pharmaceutical ingredient (API):

1	Loperamide UNII 77TI35393C - LOPERAMIDE HYDROCHLORIDE
	By binding to opiate receptors in the gut wall, loperamide hydrochloride reduces propulsive peristalsis, increases intestinal transit time and enhances resorption of water and electrolytes. Loperamide increases the tone of the anal sphincter, which helps reduce faecal incontinence and urgency.
	Read more about Loperamide

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-0217	Capsule	Slp-Diazip Capsules CAP 2 mg 1 x 10 (in PVC-Alu blister)	Capsule 50 CMS-PP-343280 SLP-DIAZIP CAPSULES LOPERAMIDE HYDROCHLORIDE 2MG EACH CAPSULE CONTAINS LOPERAMIDE 2MG EXCIPIENTS Lactose monohydrate, Microcrystalline cellulose, Maize starch, Colloidal Anhydrous Silica, Purified Talc, B4-0217 Drugs Imported Products 1X10 Over The Counter (OTC) 7/11/2023 SUITELIFE PHARMACEUTICALS LTD, 4 ayo davis close off ekolonu street, surulere, lagos 8129419809 suitelifepharma@yahoo.com Jash Pharma Private Limited, PLOT NO . 143 / 144, SURAT SPECIAL ECONOMIC ZONE, NEAR SACHIN RAILWAY STATION, SACHIN, DIST- SURAT - 394230 GUJARAT (INDIA), India	21/12/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A07DA03	Loperamide	A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07D Antipropulsives → A07DA Antipropulsives
Discover more medicines within A07DA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-0217